{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-005294","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2021-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.967706+00:00","generated_at":"2026-06-27T23:19:18.484689+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clearside reports positive safety results from OASIS Phase 1/2a trial of CLS-AX for wet AMD; dose escalation to 0.5 mg","bullets":["Cohort 2 (0.1 mg CLS-AX, n=5) well-tolerated: no serious adverse events, no treatment-related AEs, no vitreous dispersion.","Combined Cohorts 1 & 2 (n=11): 36% of patients had no retreatments for ≥3 months; 55% for ≥2 months.","Mean best corrected visual acuity (BCVA) and central subfield thickness (CST) were stable in the first two cohorts.","Safety Monitoring Committee approved escalation to Cohort 3 (0.5 mg CLS-AX); patient screening has begun."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-005294","json":"https://secwatch.observer/filing/0000950170-21-005294.json","markdown":"https://secwatch.observer/filing/0000950170-21-005294.md","text":"https://secwatch.observer/filing/0000950170-21-005294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017021005294/0000950170-21-005294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017021005294/clsd-20211221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:19:18.484689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}